Patent EP-2290103-A3 (EP)
Inventor: TUERECI OEZLEM
IPC: C12Q1/68
Filed: 2005-05-11
Abstract: Composition comprises a substance which inhibits the expression or activity of a tumor-associated antigen, where the antigen has a sequence coded by a nucleic acid with specifically defined sequence. Composition comprises a substance (S1) which inhibits the expression or activity of a tumor-associated antigen (A1), where (A1) has a sequence coded by: a nucleic acid (I) with one of 29 specifically defined sequences given in the specification (SEQ ID 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 69, 71, 73, 75, 79, 80, 85, 87, 102, 104, 106, 108, 110 or 112); a nucleic acid (II) hybridizing to (I); a nucleic acid (III) degenerate with respect to (I) or (II); or a nucleic acid (IV) complementary to (I), (II) or (III). Independent claims are also included for the following: (1) composition comprising a substance (S2) with tumor-inhibiting activity selective for cells which exhibit an expression (optionally abmormal) of (A1); (2) composition containing a substance (S3) increasing the quantity of complexes between a human leukocyte antigen (HLA) and (A1) or its fragment; (3) diagnosis (M1) of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising the detection, in a biological sample isolated from a patient, of (I) or its fragment, (A1) or its fragment, (Ab) or its fragment, or cytotoxic or helper-T-lymphocytes specific for (A1) or its fragment; (4) treatment of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising removal of a patient sample with immunoreactive cells, contacting the sample with (C1) under conditions favoring the production of cytolytic or cytokine-releasing T-cells against (A1), and importing the cytolytic or cytokine-releasing T-cells into the patient in a quantity sufficient to promote lysis of cells expressing (A1); (5) treatment (M2) of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising identifying (I) expressed by cells associated with the disease, transfection of a host cell with (I), cultivating the host cell for expression of (I) and importing the host cell or its extract into the patient in a quantity to increase the immune reaction against the cells; (6) treatment of diseases characterized by the expression or abnormal expression of tumor-associated antigens comprising identifying cells from the patient which express abnormal amounts of (A1), isolating a sample of the cells, cultivating the cells and importing the cells into the patient in a quantity to provoke an immune reaction against the cells; (7) nucleic acids (I); (8) nucleic acids (Ia) coding for a protein or peptide (Ia) with any of 27 specifically defined sequences given in the specification (SEQ ID 61-68, 70, 72, 74, 81, 82, 86, 88, 96-101, 103, 105, 107, 109, 111 or 113); (9) host cells which contain (I), optionally further containing nucleic acid coding for HLA; (10) protein or peptide (V) expressed by (I), or with sequence as in (Ia), their fragments, immunogenic fragments, and fragments binding to human HLA or human antibodies; (11) antibody (Ab1), specifically binding to (V); (12) antibody (Ab2), specifically binding to a complex of (V) and MHC which binds to (V), but not to either individual component; (13) conjugate of (Ab1) or (Ab2) and a therapeutic or diagnostic agent, e.g. a toxin; and (14) a kit for carrying out (M1). ACTIVITY : Cytostatic; Immunostimulant. No biological data given. MECHANISM OF ACTION : Tumor-associated antigen inhibitor; Cell death inducer; Complement activator (claimed).